The U.S. Food and Drug Administration, along with European health officials, has informed that the popular drug and brand Zantac acid, or another generic ranitidine formulation, may include a possible carcinogen, N-nitrosodimethylamine (NDMA). NDMA is an industrialized chemical commonly found in petroleum-based products such as gasoline, diesel, and industrial lubricants.
NDMA is also a byproduct of the production of pesticides and other compounds and is labeled as a potential carcinogen. Zantac and several other ranitidine acid stocks have been examined to contain NDMA levels that are 3,000 to 26,000 times more powerful than those permitted by the FDA.
People who develop cancer after taking Zantac (ranitidine) can sue the Zantac manufacturer or claim a generic Zantac lawsuit against them to seek some compensation for the problem they are suffering from other manufacturers.
Image Source: Google
People who may be eligible for the benefits include people who have used Zantac without a prescription with other generic medicines, or who have had a regular brand of ranitidine for at least 60 days and who have been diagnosed with:
- Bladder cancer
- Testicular cancer
- Testicular cancer in children
- Kidney cancer
- Prostate cancer
- Breast cancer
- Thyroid cancer
People who were diagnosed with one of these cancers more than 6 months after stopping ranitidine use but had taken prescription medicine or Zantac or store brands of ranitidine, for more than 1 year on a regular basis.
Damages awarded in past drug injury cases have included:
- Medical costs
- Lost wages
- Pain and suffering
- Punitive damages
- Wrongful death